Integer Holdings Corporation (NYSE:ITGR) Shares Bought by Natixis Advisors LLC

Key Points

• Natixis Advisors LLC increased its stake in Integer Holdings Corporation by 117.7%, acquiring an additional 50,924 shares during the first quarter, bringing its total to 94,202 shares valued at approximately $11.1 million.
• Several large investors, including TD Private Client Wealth and Bessemer Group, have also increased their positions in Integer, with institutional investors owning 99.29% of the company's stock.
• Integer's recent earnings report showed revenue of $476 million but missed EPS estimates by $0.02, leading to varied analyst ratings, including upgrades that resulted in a consensus target price of $140.25.

Natixis Advisors LLC increased its position in shares of Integer Holdings Corporation (NYSE:ITGR - Free Report) by 117.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 94,202 shares of the medical equipment provider's stock after purchasing an additional 50,924 shares during the quarter. Natixis Advisors LLC owned approximately 0.27% of Integer worth $11,117,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Opal Wealth Advisors LLC purchased a new stake in Integer during the 1st quarter worth about $28,000. AdvisorNet Financial Inc purchased a new position in Integer during the first quarter valued at approximately $28,000. Bessemer Group Inc. increased its holdings in Integer by 73.1% during the 1st quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 125 shares during the period. Sterling Capital Management LLC boosted its holdings in Integer by 472.9% in the 4th quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 279 shares during the period. Finally, Contravisory Investment Management Inc. boosted its stake in Integer by 103.9% in the first quarter. Contravisory Investment Management Inc. now owns 1,413 shares of the medical equipment provider's stock worth $167,000 after buying an additional 720 shares in the last quarter. Hedge funds and other institutional investors own 99.29% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Benchmark decreased their price objective on Integer from $150.00 to $140.00 and set a "buy" rating on the stock in a report on Friday, April 25th. Citigroup raised Integer from a "hold" rating to a "strong-buy" rating and raised their target price for the stock from $133.00 to $140.00 in a research note on Thursday, May 22nd. Wall Street Zen raised Integer from a "sell" rating to a "hold" rating in a research report on Monday, May 19th. Truist Financial reduced their target price on Integer from $145.00 to $137.00 and set a "buy" rating on the stock in a research note on Friday, July 25th. Finally, Raymond James Financial dropped their price target on Integer from $150.00 to $143.00 and set an "outperform" rating for the company in a research note on Friday, July 25th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Integer currently has a consensus rating of "Moderate Buy" and a consensus target price of $140.25.

Insider Activity at Integer

In other news, Director Donald J. Spence sold 14,739 shares of the business's stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $120.38, for a total value of $1,774,280.82. Following the transaction, the director directly owned 18,781 shares in the company, valued at $2,260,856.78. The trade was a 43.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Martin C. Maxwell sold 8,720 shares of Integer stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $120.56, for a total value of $1,051,283.20. Following the sale, the director directly owned 22,170 shares in the company, valued at $2,672,815.20. This trade represents a 28.23% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.16% of the company's stock.

Integer Stock Performance

NYSE:ITGR traded up $0.75 during trading hours on Thursday, reaching $106.11. The company had a trading volume of 90,108 shares, compared to its average volume of 491,697. The firm has a market cap of $3.72 billion, a price-to-earnings ratio of 46.72, a PEG ratio of 0.85 and a beta of 1.02. The company has a current ratio of 3.41, a quick ratio of 2.18 and a debt-to-equity ratio of 0.72. The firm's 50 day moving average price is $117.14 and its 200-day moving average price is $122.22. Integer Holdings Corporation has a 52 week low of $104.93 and a 52 week high of $146.36.

Integer (NYSE:ITGR - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.02). Integer had a net margin of 4.61% and a return on equity of 12.27%. The business had revenue of $476.00 million for the quarter, compared to analysts' expectations of $464.37 million. During the same period in the previous year, the company earned $1.30 EPS. Integer's revenue for the quarter was up 11.4% compared to the same quarter last year. On average, analysts forecast that Integer Holdings Corporation will post 6.01 EPS for the current year.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.